Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5442336 | 1.00 | HTR6 (0.68) | HTR6SLC6A4MEN1CYP3A4MAPT | |
| Hydrochloric Acid SCHEMBL27533549 | 0.99 | HTR6 (0.68) | HTR6SLC6A4MEN1CYP3A4MAPT | |
| Hydrochloric Acid SCHEMBL27493748 | 0.99 | HTR6 (0.68) | HTR6SLC6A4MEN1CYP3A4MAPT | |
| SCHEMBL24178316 | 0.88 | HTR6 (0.69) | HTR6SLC6A4MEN1CYP3A4MAPT | |
| SCHEMBL24178288 | 0.88 | HTR6 (0.69) | HTR6SLC6A4MEN1CYP3A4MAPT | |
| SCHEMBL30361714 | 0.88 | HTR6 (0.69) | HTR6SLC6A4MEN1CYP3A4MAPT | |
| SCHEMBL23802750 | 0.86 | HTR6 (0.68) | HTR6SLC6A4MEN1CYP3A4MAPT | |
| SCHEMBL23802829 | 0.86 | HTR6 (0.68) | HTR6SLC6A4MEN1CYP3A4MAPT | |
| SCHEMBL1445683 | 0.81 | HTR6 (1.00) | HTR6SLC6A4MEN1CYP3A4MAPT | |
| SCHEMBL30675329 | 0.81 | HTR6 (1.00) | HTR6SLC6A4MEN1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206186-B2 | 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of inflammatory or immunological disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| CN-1802159-B | 2-phenoxy-and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological diseases | ACTIMIS PHARMACEUTICALS INC | 2013-04-24 | — | — | CN | disclosed |
| CN-102146053-A | 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of inflammatory or immunological disorders | ACTIMIS PHARMACEUTICALS INC | 2011-08-10 | — | — | CN | disclosed |
| US-7674797-B2 | 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-7674797-B2 | 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-20090286771-A1 | 2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological Disorders | LI YINGFU | 2009-11-19 | — | — | US | disclosed |
| US-20090286771-A1 | 2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological Disorders | LI YINGFU | 2009-11-19 | — | — | US | disclosed |
| EP-1608374-B9 | 2-PHENOXY- AND 2-PHENYLSULFOMAMIDE DERIVATIVES WITH CCR3 ANTAGONISTIC ACTIVITY FOR THE TREATMENT OF ASTHMA AND OTHER INFLAMMATORY OR IMMUNOLOGICAL DISORDERS | ACTIMIS PHARMACEUTICALS INC (US) | 2009-04-08 | — | — | EP | disclosed |
| EP-1997495-A1 | 2-phenoxy- and 2-phenylsulfanyl-benzenesulfonamide derivatives with ccr3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders | Actimis Pharmaceuticals, Inc., (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1608374-B1 | 2-PHENOXY- AND 2-PHENYLSULFOMAMIDE DERIVATIVES WITH CCR3 ANTAGONISTIC ACTIVITY FOR THE TREATMENT OF ASTHMA AND OTHER INFLAMMATORY OR IMMUNOLOGICAL DISORDERS | ACTIMIS PHARMACEUTICALS INC (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20070155725-A1 | 2-Phenoxy- and 2-phenylsulfomamide derivatives with ccr3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders | AXIKIN PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155725-A1 | 2-Phenoxy- and 2-phenylsulfomamide derivatives with ccr3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders | AXIKIN PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| CN-1802159-A | 2-phenoxy-and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological diseases | ACTIMIS PHARMACEUTICALS INC (US) | 2006-07-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286771-A1 | 2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological Disorders | CCR3, CCR2, CCR1 | HTR6 152/4885SLC6A4 2134/4885MEN1 4082/4885 |
| US-20070155725-A1 | 2-Phenoxy- and 2-phenylsulfomamide derivatives with ccr3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders | CCR3, CCR1, CCR2 | HTR6 695/4885SLC6A4 3520/4885MEN1 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.